Effector Selects Lead Cancer Compound, Looks Ahead To Combo Regimens
This article was originally published in The Pink Sheet Daily
Executive Summary
Leading the way in translation regulation, biotech moves its first candidate into clinical development in solid tumors, but plans quick move also into lymphoma.